GlassScriptPhysician profile
Takashi Shinha
NPI 1588900468
$11,842.94
in general payments reported to CMS, 2019-2025
20 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $1,376 · 2021: $2,305 · 2022: $2,059 · 2023: $1,581 · 2024: $1,626 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008 · Education: $1.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,008.17 |
| Education | $1.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $3,778.08 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $1,530.06 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Cumberland Pharmaceuticals, INC. | $1,464.90 | 2019-2025 | Vibativ |
| Gilead Sciences, INC. | $1,178.39 | 2019-2025 | Veklury, Biktarvy |
| Viiv Healthcare Company | $916.20 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $660.26 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $470.49 | 2019-2025 | Capvaxive, Delstrigo, Dificid |
| Janssen Products, LP | $379.95 | 2020-2022 | |
| Melinta Therapeutics, LLC | $364.84 | 2019-2024 | Kimyrsa, Vabomere, Rezzayo |
| Allergan, INC. | $310.03 | 2019-2020 | |
| Shionogi INC | $257.28 | 2024-2025 | Fetroja |
| Smith+Nephew, INC. | $172.67 | 2019-2021 | |
| Vyera Pharmaceuticals, LLC | $90.95 | 2020-2022 | |
| Emd Serono, INC. | $62.73 | 2019-2024 | |
| Astellas Pharma US INC | $60.44 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $42.55 | 2023 | |
| Paratek Pharmaceuticals, INC. | $30.49 | 2019-2021 | |
| Novo Nordisk INC | $29.37 | 2025 | Ozempic |
| Ferring Pharmaceuticals INC. | $23.47 | 2023 | Rebyota |
| Kowa Pharmaceuticals America, INC. | $19.79 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Takashi Shinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.